CSTONE PHARMACEUTICALS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9 HKD | 0.00% |
|
+5.88% | -60.35% |
| Apr. 24 | Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% | MT |
| Apr. 23 | CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on CStone Pharmaceuticals
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.75% | 4 M€ | -27.92% | ||
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 34 M€ | +2.14% | - |
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8331
CNY
Average target price
3.186
CNY
Spread / Average Target
+282.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.35% | 146M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2616 Stock
- Funds and ETFs CStone Pharmaceuticals
